Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

90 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Aspacytarabine for the treatment of patients with AML unfit for intensive chemotherapy: a phase 2 study.
Altman JK, Zuckerman T, Koprivnikar J, McCloskey J, Kota V, Keng M, Frankfurt O, Abaza Y, Bixby DL, Emadi A, Burch M, Bhatnagar B, Luger SM, Percival ME, Wolach O, Craig M, Ganzel C, Roboz G, Levi I, Gourevitch A, Flaishon L, Tessler S, Blumberg C, Gengrinovitch S, Ben Yakar R, Rowe JM. Altman JK, et al. Among authors: bixby dl. Blood Adv. 2023 Dec 26;7(24):7494-7500. doi: 10.1182/bloodadvances.2023010943. Blood Adv. 2023. PMID: 37903324 Free PMC article. Clinical Trial.
Genomic analysis of adult B-ALL identifies potential markers of shorter survival.
Patel S, Mason CC, Glenn MJ, Paxton CN, South ST, Cessna MH, Asch J, Cobain EF, Bixby DL, Smith LB, Reshmi S, Gastier-Foster JM, Schiffman JD, Miles RR. Patel S, et al. Among authors: bixby dl. Leuk Res. 2017 May;56:44-51. doi: 10.1016/j.leukres.2017.01.034. Epub 2017 Feb 3. Leuk Res. 2017. PMID: 28193567
Analysis of the potential effect of ponatinib on the QTc interval in patients with refractory hematological malignancies.
Sonnichsen D, Dorer DJ, Cortes J, Talpaz M, Deininger MW, Shah NP, Kantarjian HM, Bixby D, Mauro MJ, Flinn IW, Litwin J, Turner CD, Haluska FG. Sonnichsen D, et al. Cancer Chemother Pharmacol. 2013 Jun;71(6):1599-607. doi: 10.1007/s00280-013-2160-7. Epub 2013 Apr 23. Cancer Chemother Pharmacol. 2013. PMID: 23609479 Free PMC article. Clinical Trial.
Pharmacologic inhibition of the Menin-MLL interaction blocks progression of MLL leukemia in vivo.
Borkin D, He S, Miao H, Kempinska K, Pollock J, Chase J, Purohit T, Malik B, Zhao T, Wang J, Wen B, Zong H, Jones M, Danet-Desnoyers G, Guzman ML, Talpaz M, Bixby DL, Sun D, Hess JL, Muntean AG, Maillard I, Cierpicki T, Grembecka J. Borkin D, et al. Among authors: bixby dl. Cancer Cell. 2015 Apr 13;27(4):589-602. doi: 10.1016/j.ccell.2015.02.016. Epub 2015 Mar 26. Cancer Cell. 2015. PMID: 25817203 Free PMC article.
Characterizing and targeting PDGFRA alterations in pediatric high-grade glioma.
Koschmann C, Zamler D, MacKay A, Robinson D, Wu YM, Doherty R, Marini B, Tran D, Garton H, Muraszko K, Robertson P, Leonard M, Zhao L, Bixby D, Peterson L, Camelo-Piragua S, Jones C, Mody R, Lowenstein PR, Castro MG. Koschmann C, et al. Oncotarget. 2016 Oct 4;7(40):65696-65706. doi: 10.18632/oncotarget.11602. Oncotarget. 2016. PMID: 27582545 Free PMC article.
90 results